MedTrace Logo

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

NCT02409524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-01-22

No results posted yet for this study

Summary

This is an open-label, single site, Phase IIA clinical trial to investigate the safety and efficacy of an individualized anti-cancer vaccine (CRCL-AlloVax) in advanced HCC patients.

Conditions

  • Advanced Adult Hepatocellular Carcinoma

Interventions

BIOLOGICAL

AlloVax

Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)

BIOLOGICAL

AlloStim

AlloStim (ID) injection AlloStim (IV) infusion

BIOLOGICAL

CRCL

Autologous tumor-derived chaperone protein mixture

Sponsors & Collaborators

  • Mirror Biologics, Inc.

    lead INDUSTRY

Principal Investigators

  • Wirote Lausoontornsiri, MD · National Cancer Institute (NCI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-06-30
Completion
2019-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02409524 on ClinicalTrials.gov